Table 1

Patients and tumour characteristics

Variable

Number of patients (%)


Number of the patients

125 (aged 30-90, mean 57, 5)

Grade

I

10 (8%)

II

66 (52, 8%)

III

49 (39, 2%)

Axillary nodal status

N0

64 (51, 2%)

≥N1

50 (40%)

Unknown

11 (8, 8%)

Estrogen receptor status (ER)1)

Positive

80 (64%)

Negative

45 (36%)

Progesterone receptor status (PR)1)

Positive

82 (65, 6%)

Negative

43 (34, 4%)

Ki-67 status2)

low ≤ 15%

63 (50,4%)

intermediate 16-30%

41 (32,8%)

high > 30%

20 (16%)

one value missing

1 (8%)

Histologic type

Ductal

110 (88%)

Lobular

10 (8%)

Subtypes

5 (4%)

Her23)

IHC positive (2+ and 3+)

25 (20%)

IHC negative (0 and 1+)

100 (80%)

CK 5/64)

Triple-negative (ER-, PR-, Her2-)

35 (28%)

Basal-like carcinoma (ER-, PR-, Her2-, CK5/6+)

20 (16%)

Treatment after operation

Chemotherapy 27

(21,6%)

Radiation 59

(47,2%)

Hormonal therapy 24

(19,2%)


1,4) Cut off point used for ER and PR immunohistochemistry is 10% of positively stained tumour nuclei and 10% cytoplasmic staining for CK5/6.

2) Proliferation index according to St Gallen Consesus (Goldhirsch et al 2009).

3) Scoring of HER2 immunohistochemistry: Score 0: no staining is observed or cell membrane staining is observed in less than 10% of tumour cells. Score 1+: a faint perceptible membrane staining can be detected in more than 10% of the tumour cells or cells are only stained in part of their membrane. Score 2+: a weak to moderate complete membrane staining is observed in more than 10% of the tumour cells. Score 3+: a strong complete membrane staining is observed in more than 10% of the tumour cells.

Boström et al. BMC Cancer 2011 11:348   doi:10.1186/1471-2407-11-348

Open Data